HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

Lancet
Paul M RidkerJUPITER Trial Study Group

Abstract

HDL-cholesterol concentrations are inversely associated with occurrence of cardiovascular events. We addressed, using the JUPITER trial cohort, whether this association remains when LDL-cholesterol concentrations are reduced to the very low ranges with high-dose statin treatment. Participants in the randomised placebo-controlled JUPITER trial were adults without diabetes or previous cardiovascular disease, and had baseline concentrations of LDL cholesterol of less than 3.37 mmol/L and high-sensitivity C-reactive protein of 2 mg/L or more. Participants were randomly allocated by a computer-generated sequence to receive rosuvastatin 20 mg per day or placebo, with participants and adjudicators masked to treatment assignment. In the present analysis, we divided the participants into quartiles of HDL-cholesterol or apolipoprotein A1 and sought evidence of association between these quartiles and the JUPITER primary endpoint of first non-fatal myocardial infarction or stroke, hospitalisation for unstable angina, arterial revascularisation, or cardiovascular death. This trial is registered with ClinicalTrials.gov, number NCT00239681. For 17,802 patients in the JUPITER trial, rosuvastatin 20 mg per day reduced the incidence of the prima...Continue Reading

References

Jan 19, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Alan R TallNan Wang
Mar 28, 2007·The New England Journal of Medicine·Steven E NissenUNKNOWN ILLUSTRATE Investigators
Mar 28, 2007·The New England Journal of Medicine·John J P KasteleinUNKNOWN RADIANCE 1 Investigators
Sep 28, 2007·The New England Journal of Medicine·Philip BarterUNKNOWN Treating to New Targets Investigators
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Jan 5, 2008·Journal of the American College of Cardiology·Emil M deGomaPaul A Heidenreich
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Feb 12, 2009·European Journal of Clinical Nutrition·L A FrassettoA Sebastian
Mar 31, 2009·The New England Journal of Medicine·Robert J GlynnPaul M Ridker

❮ Previous
Next ❯

Citations

Sep 26, 2013·European Journal of Clinical Pharmacology·D Macías Saint-GeronsF Catalá-López
Feb 23, 2011·Cardiovascular Drugs and Therapy·John D HorowitzWillem J Remme
Nov 2, 2011·Internal and Emergency Medicine·Diego Vanuzzo
Nov 2, 2011·Internal and Emergency Medicine·Claudio Cimminiello
Sep 10, 2013·European Heart Journal·Guenther SilbernagelWinfried März
Sep 26, 2013·European Heart Journal·Prediman K Shah
May 4, 2011·Current Opinion in Lipidology·Bela F AsztalosErnst J Schaefer
Mar 4, 2011·Science Translational Medicine·David A Fryburg, Maria T Vassileva
Mar 1, 2011·Therapeutic Advances in Chronic Disease·Leiv Ose
Jun 16, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Takao MaruyamaToshiaki Hasuike
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Natalie J Carter
Aug 24, 2011·World Journal of Cardiology·Michael S Kostapanos, Moses S Elisaf
Nov 26, 2013·Current Atherosclerosis Reports·Benoit J Arsenault, S Matthijs Boekholdt
May 21, 2014·Best Practice & Research. Clinical Endocrinology & Metabolism·Peter P TothMaciej Banach
Jun 20, 2013·Cholesterol·Anouar Hafiane, Jacques Genest
Jun 22, 2014·Current Cardiology Reports·Carlos G Santos-Gallego, Robert S Rosenson
Mar 27, 2013·American Journal of Therapeutics·Arshag D Mooradian
Nov 30, 2014·Endocrinology and Metabolism Clinics of North America·Carlos G Santos-GallegoRobert S Rosenson
Jun 4, 2014·Current Atherosclerosis Reports·Angela PirilloAlberico Luigi Catapano
Aug 21, 2013·Nature Reviews. Cardiology·Antonio M Gotto, Jennifer E Moon
Feb 20, 2013·Current Cardiology Reports·Melvyn Rubenfire, Robert D Brook
Oct 12, 2011·Journal of Cardiovascular Medicine·Gian Francesco MuredduLeonardo De Luca
Jan 5, 2012·Critical Reviews in Clinical Laboratory Sciences·Fathimath FaizFrank M van Bockxmeer
Aug 1, 2015·International Journal of Molecular Sciences·Peiqiu CaoZhengquan Su
Nov 9, 2011·Expert Review of Cardiovascular Therapy·Stephen J NichollsYu Kataoka
Apr 8, 2014·Expert Opinion on Pharmacotherapy·Stephen J NichollsRishi Puri
Mar 9, 2013·Expert Review of Cardiovascular Therapy·Steven Campbell, Jacques Genest
Dec 3, 2011·Expert Opinion on Drug Safety·Rahul YadavHandrean Soran
Aug 21, 2012·The Canadian Journal of Cardiology·Pamela M Katz, Lawrence A Leiter
Aug 13, 2011·Revista española de cardiología·José Ramón González-JuanateyVicente Bertomeu
Nov 26, 2010·Lancet·Christoph H SaelyHeinz Drexel
Jul 27, 2010·Lancet·Derek J HausenloyDerek M Yellon
Oct 2, 2015·Atherosclerosis·Samantha A ReinaJ A Chris Delaney
Sep 18, 2015·Atherosclerosis·Carlos G Santos-Gallego

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.